VTVT News and Press, vTv Therapeutics Inc. From 12/13/22

Steven Tuch, Chief Financial Officer HIGH POINT, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment...

vTv Therapeutics press release ( NASDAQ: VTVT ): Q3 GAAP EPS of -$0.05. The Company’s cash position as of September 30, 2022, was $15.3 million compared to $13.4 million as of December 31, 2021. For further details see: vTv Therapeutics GAAP EPS ...

Company on-track to initiate Phase 3 clinical trials of TTP399 in the first quarter of 2023 Industry veteran Paul Sekhri joins the Company as President, Chief Executive Officer, and member of the Board of Directors Agreements with CinRx Pharma and a subsidiar...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips After becoming very popular with retail investors on social media, Revlon (NYSE: REV ) stock will be delisted soon . The cosmetics company declared bankruptcy in June, citing its huge debt and supply-chain issues. ...

vTv Therapeutics press release ( NASDAQ: VTVT ): Q2 GAAP EPS of -$0.04. The Company’s cash position as of June 30, 2022, was $17.9M compared to $13.4M as of December 31, 2021. For further details see: vTv Therapeutics GAAP EPS of -$0.04

Paul Sekhri appointed as President, Chief Executive Officer and Board member. Entered into agreements with CinRx Pharma and a subsidiary to purchase $10 million in stock and to leverage CinRx’s industry experience to collaborate in overseeing TTP399 clinical trials. ...

Paul Sekhri has been appointed as president and CEO of clinical-stage biopharmaceutical company vTv Therapeutics ( NASDAQ: VTVT ). Sekhri assumes the role on August 1, 2022, replacing interim CEO Rich Nelson, who will continue as EVP, Corporate Development and as a member ...

HIGH POINT, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced that Paul Sekhri will lead the compa...

vTv Therapeutics ( NASDAQ: VTVT ) is raising $10M via an equity investment by CinPax, a unit of CinRx Pharma. Under the agreements, CinPax acquired ~4.15M class A Common shares of vTv at ~$2.41 apiece. About $6M will be paid in cash at closing, and the remaining $...

HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC (“CinPax”), a subsidiary of CinRx Pharma, LLC (“CinRx”). Under the terms of the...